This is an exciting time for cataract surgeons. Advances in glaucoma management mean we no longer must view cataract and glaucoma surgeries as separate interventions. We can take a more proactive, comprehensive approach to patient care and continue to expand our procedural offerings.

Selective laser trabeculoplasty and direct selective laser trabeculoplasty with the Voyager system (Alcon) have become first-line therapies. MIGS has redefined what is possible in the OR. These procedures help us take a more proactive role in glaucoma care. They lower IOP while maintaining the safety patients expect from cataract surgery. Because glaucoma is often underdiagnosed and undertreated, cataract surgery offers an ideal opportunity to intervene early in the disease process.

Choosing the right patients is critical. Understanding disease severity, risk factors, target IOP, and ocular anatomy helps us tailor treatment precisely and purposefully. The contributors to this month’s cover focus share decision-making frameworks, practical pearls for combining procedures, and insights into candidate selection to achieve the best results.

This edition of CRST also explores the philosophy of interventional glaucoma—shifting treatment earlier in the disease course. Topical medication is used as a bridge to other procedures to maintain round-the-clock IOP control, reduce the risk of visual field defects, and delay or avoid the need for more invasive surgery. In this era, when patient adherence remains a challenge and delayed treatment carries risks, interventional glaucoma offers a way forward.

As Guest Medical Editor, I hope this issue inspires you to consider how adding glaucoma procedures to your cataract workflow can improve outcomes and reshape your approach to comprehensive anterior segment care. It has been a wonderful journey, and I am excited to share this passion with you.